The clinical effects of prolonged treatment of patients with advanced cancer with low-dose subcutaneous interleukin-2 [corrected]

Thirty-five patients with advanced malignant disease have been treated as outpatients with increasing doses (0.1-100 mcg) of interleukin 2 (IL2) by once daily self-administered subcutaneous (s.c.) injection, 5 days weekly for 8 weeks followed by a 4 week observation period. Systemic side effects wer...

Descripción completa

Detalles Bibliográficos
Autores principales: Stein, R. C., Malkovska, V., Morgan, S., Galazka, A., Aniszewski, C., Roy, S. E., Shearer, R. J., Marsden, R. A., Bevan, D., Gordon-Smith, E. C.
Formato: Texto
Lenguaje:English
Publicado: Nature Publishing Group 1991
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1971786/
https://www.ncbi.nlm.nih.gov/pubmed/1997106

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1971786/
https://www.ncbi.nlm.nih.gov/pubmed/1997106

Ejemplares similares